Additionally, semaglutide may have direct effects on the blood vessels, making them more relaxed and less resistant to blood flow
Its formulated at the right concentration to deliver results without irritation
Damluji AA, Alfaraidhy M, AlHajri N, Rohant NN, Kumar M, Al Malouf C, Bahrainy S, Ji Kwak M, Batchelor WB, Forman DE, Rich MW, Kirkpatrick J, Krishnaswami A, Alexander KP, Gerstenblith G, Cawthon P, deFilippi CR, Goyal P
GLP-1 receptor agonists like semaglutide and tirzepatide act on incretin pathways through GLP-1 and GIP receptors, with central appetite suppression and slowed gastric emptying as primary mechanisms
N Engl J Med 326:13161322
GLP-1 Receptor Agonist Market Key Players Novo Nordisk A/S (Ozempic, Wegovy, Rybelsus, Victoza, Saxenda) Eli Lilly and Company (Mounjaro, Zepbound, Trulicity) AstraZeneca PLC (Byetta, Bydureon BCise) Sanofi SA GlaxoSmithKline plc Pfizer Inc